by Aptamers are short, single-stranded DNA or RNA oligonucleotides that fold into unique three-dimensional structures. They are selected through an in vitro selection process called Systematic Evolution of Ligands by EXponential enrichment (SELEX) to bind a wide range of targets with high affinity and specificity. Aptamers have advantages over antibodies such as low immunogenicity, high stability, and low production cost. The ability to specifically identify molecular targets has made aptamers an attractive alternative to antibodies for diagnostics and therapeutics. They are increasingly being evaluated for applications in fields like clinical diagnostics, toxicology testing, and targeted drug delivery.
The global Aptamers Market is estimated to be valued at US$ 6265.49 Mn in 2023 and is expected to exhibit a CAGR of 3.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends in the aptamers market size is the increasing research on aptamers for applications in precision medicines. Aptamers provide several advantages for targeted drug delivery such as high affinity and specificity for molecular targets, lack of immunogenicity, ability to penetrate tissues, and low cost of production. Several pharmaceutical companies are engaged in R&D of aptamer-based drugs and diagnostic agents for diseases like cancer, cardiovascular diseases, ocular diseases, and inflammatory diseases. For instance, Phase 1 clinical trial of an aptamer-drug conjugate (AS1411-Grb2) for acute myeloid leukemia treatment was initiated by Antisoma Research Ltd. in 2020. Such increasing pharmaceutical applications of aptamers are expected to drive market growth over the forecast period.
Porter’s Analysis
Threat of new entrants: The aptamers market requires substantial R&D investments and regulatory approvals, acting as a barrier to entry for new players.
Bargaining power of buyers: Buyers have moderate bargaining power due to the specialized nature of aptamers and limited alternatives. However, established key players can leverage economies of scale.
Bargaining power of suppliers: A few key players dominate the supply side. Suppliers thus have moderate bargaining power.
Threat of new substitutes: Though some alternative technologies exist, no direct substitutes provide the unique advantages of aptamers, limiting threat from substitutes.
Competitive rivalry: The market is moderately competitive with the presence of multiple global and local players. Companies compete based on technological innovations, product differentiation, and collaborations.
Key Takeaways
The global Aptamers market is expected to witness high growth. The global Aptamers Market is estimated to be valued at US$ 6265.49 Mn in 2023 and is expected to exhibit a CAGR of 3.3% over the forecast period 2023 to 2030.
Regional analysis: The aptamers market is dominated by North America, followed by Europe. This can be attributed to growing research funding, technological advancements, and rising demand for personalized medicine in these regions. Asia Pacific is poised to witness the highest growth during the forecast period owing to increasing contract research and manufacturing activities, and improving healthcare infrastructure in emerging countries.
Key players: Key players operating in the aptamers market are ContiTech Australia Pty. Ltd., Endless Belt Service Pty Ltd., Fenner Dunlop Australia Pty Ltd, Flexible Steel Lacing Company (Flexco), Kinder Australia Pty Ltd., Mato GmbH & Co. KG., Minprovise Pty Ltd, Nepean Engineering & Innovation Pty Ltd., Reliable Conveyor Belt Pty. Ltd., Rema Tip Top Australia, Forbo Siegling PTY. Ltd., and others.
